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Objective: The studies that have extensively evaluated the relation between adipokines andmetabolic parameters
in acromegaly treatment are quite discordant. We aimed to evaluate and correlate a set of selected adipokines,
known to have a metabolic role, with the disease activity, metabolic status and treatment modalities.
Design:Data of 56 consecutive acromegalic patients (31M and 25 F; aged 54±12 years), admitted to the section
of Endocrinology of the University of Palermo during the years 2005–2014, including 16 newly diagnosed
untreated (ND), 21 during therapy with somatostatin analogues (SA), 12 with pegvisomant (PE) and 7 after
surgical treatment (SU), grouped into uncontrolled (group A: No. 33) and controlled (group B: No. 23) were
evaluated. Anthropometric and metabolic parameters, insulin sensitivity indexes, visceral adiposity index
(VAI), leptin, soluble leptin receptor, adiponectin, visfatin, resistin, adipsin and non-esteriﬁed fatty acids
(NEFAs) were assessed. In a subgroup of 21 subjects, the insulin sensitivity index (M value) derived from
euglycemic clamp was calculated.
Results: Group A showed higher Homa-IR (p b 0.001), VAI (p b 0.001), triglycerides (p b 0.001), visfatin (p b 0.001),
andNEFAs (pb 0.001) and lower ISIMatsuda (pb 0.001),Mvalue (pb 0.001), HDL cholesterol (pb 0.001) and leptin
(p b 0.001) than group B.ND patients showed higher VAI, triglycerides, Homa-IR, and visfatin and lower ISIMatsuda,
M-value, and leptin compared to other groups (all p b 0.050), while no differenceswere found among SA, PE and SU
patients. IGF-1 (p = 0.048), M-value (p = 0.0029) and VAI (p = 0.010) were independently associated with
visfatin, while only ISI Matsuda (p = 0.019) was associated with leptin.
Conclusions: In acromegaly visfatin could be considered a useful index of disease activity and metabolic alterations,
such as insulin resistance and adipose dysfunction, regardless of the type of treatment.© 2015 Elsevier Ltd. All rights reserved.1. Introduction
The growthhormone (GH) hasmetabolic effects on peripheral tissues
in addition to the growth promoting role, including the stimulation of
gluconeogenesis and lipolysis, which results in increased glucose and
free fatty acid (FFA) levels and the adipose tissue is one of the key target
organs of GH action [1–3].
In acromegaly, the GH excess leads to an alteration in adipose tissue
distribution and function through a lipolytic effect and an increased FFA
ﬂux from adipose to peripheral tissues and this condition appears to be
directly associated with disease activity and insulin resistance [4,5]. Thein analogues; PE, pegvisomant;
s, non-esteriﬁed fatty acids.
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.white visceral adipose tissue produces different mediators, the
adipokines, and a strong association between metabolic risk and fat
distribution or adipokine levels has recently been documented [6]. The
adipose dysfunction, resulting in higher lipolytic activity, changes the
production and secretion of adipokines known to play a role in the path-
ogenesis of low-grade systemic inﬂammation and insulin resistance [7],
leading to a cardiovascular disease and systemicmetabolic complications
[8,9]. In this view, the relation between GH and adipokine levels could
explain the metabolic risk associated with acromegaly, although to
date the data on adipokine levels in acromegaly are discordant.
The primary outcome of this study was to evaluate a set of selected
adipokines, known to have a metabolic role [10,11], in patients with
acromegaly and to correlate them with the disease activity and the
metabolic status. In addition, we aimed to investigate the effect of
different treatment modalities on adipokine levels.
2. Materials and methods
This is a cross-sectional study. For the purpose of the study we
analyzed the data of ﬁfty-six outpatients (31 males and 25 females;
aged 54 ± 12 years, range 25–79) with acromegaly, admitted to the
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2005–2014.
A subset of patientswas already included in our previous study aimed
to investigate leptin and adiponectin levels in newly diagnosed acrome-
galic patients [4]. In the current studywehave performed amore detailed
analysis, by including other adipokines, in a larger group of patients and
during different treatment modalities, to avoid reporting data already
published. Therefore, in this paper the case load includes only 16 of 24
patients previously published and the other cases are entirely unpub-
lished. The duration of disease was established by patient interview,
patients' clinical pictures and onset of osteoarticular symptoms. Patients
with mixed GH/PRL-secreting adenoma and with deﬁciency of one or
more anterior pituitary hormones were excluded from this study to
avoid the potential impact of hormonal deﬁcit or replacement therapy
on GH, insulin growth factor-1 (IGF-1), as well as metabolic parameters.
Sixteen patients were newly diagnosed (ND), while the remain-
ing were treated with somatostatin analogues (SA, 21 patients) and
pegvisomant (PE, 12 patients) or had undergone surgery 6months previ-
ously (SU, 7 patients). Speciﬁcally, among patients treated with SA, 14
(67%) received octreotide long-acting release (LAR) (10–40 mg every
28 days) and 7 (33%) lanreotide autogel (ATG) (60–120 mg every
28 days). In the octreotide-group, 6 patientswere treatedwith amonthly
dose of 20 mg, 5 with 30 mg, 2 with 10 mg and 1 with 40 mg; in the
lanreotide-group, 4 patients were treated with a monthly dose of
120 mg, 2 with 90 mg and 1 with 60 mg of ATG. The activity of disease
at the time of the study was conﬁrmed by plasma mean GH proﬁle,
elevated age- and gender-corrected plasma IGF-1 levels and non-
suppressible GH after OGTT [12]. According to these criteria, all patients
were grouped into those with uncontrolled (group A: 33 patients,
including 16 ND, 10 SA, 5 PE, 2 SU) and controlled (group B: 23 patients,
including 11 SA, 7 PE, 5 SU) disease. Each group of patients wasmatched
by gender, BMI and WC, to avoid the interference of these variables on
metabolic evaluation.
At the time of hospitalization, all patients signed a consent form for
the scientiﬁc use of their data after a full explanation of the purpose of
the study. This study was approved by the Institutional Review Board
of the Faculty of Medicine, University of Palermo and the identity of
the participants remained anonymous during database analysis.
3. Study design
Body mass index (BMI) and systolic (SBP) and diastolic (DBP)
blood pressure were measured in all patients. WC was measured at
the midpoint between the lower rib and the iliac crest. After an over-
night fast, lipid proﬁle (total, HDL- and LDL-cholesterol, triglycerides),
hemoglobinA1c (HbA1c), mean fasting plasma GH (at least three blood
samples at 30-min intervals) and IGF-1 levels were measured. To
normalize IGF-1 in individual patients, we calculated the ratio between
the IGF-1 level and the upper limit of the normal (ULN) range for age
and gender (normal = ≤1) and the data are presented as IGF-1 ULN.
GH levels were not evaluated in patients treated with PE. OGTT was
performed in all patients by measuring plasma blood glucose, insulin
levels and GH every 30 min for 2 h after 75 g oral glucose load. Basal
insulin resistance was assessed using homeostasis model assessment of
the insulin resistance (Homa-IR) index [13]. Stimulated insulin sensitivity
wasmeasured using the insulin sensitivity index (ISI), a composite index
derived from the OGTT and validated by Matsuda and De Fronzo [14].
In a subgroup of 21 subjects (11 uncontrolled and 10 controlled,
including 7 patients ND, 6 SA, 4 PE and 4 SU) on a different day (day-2)
a euglycemic hyperinsulinemic clamp was used to determine the
insulin-sensitivity. One catheter was placed in a vein on the forearm
for administration of insulin and glucose and the second catheter was
placed in a vein of the contralateral forearm for blood samples. The
clampwas performed under standard conditions, i.e. the plasma insulin
concentration was acutely raised with an insulin priming (0–3 min:
113.6 mU/m2, 3–6 min: 80.2 mU/m2, 7–10 min: 50.4 mU/m2 of bodysurface area) for the ﬁrst 10 min of the test andmaintained by a contin-
uous infusion of insulin infusion (40mU/m2 for the remaining 110min).
The rate of peripheral glucose utilization (M value) was calculated by
dividing the glucose amount infused during the last 40 min by body
weight measured in kilograms (milligrams per kilogram per minute).
The plasma glucose concentration was held constant at basal levels by
a variable glucose infusion and under the steady-state conditions of
euglycemia the glucose infusion rate equalled glucose uptake by all the
tissues in the body and it was therefore considered a measure of tissue
sensitivity to exogenous insulin [15].
To evaluate the adipose function, in all patients we measured the
visceral adiposity index (VAI), differentiated according to sex and calcu-
lated as described [16], and the serum levels of leptin, soluble leptin
receptor (sOB-R), adiponectin, visfatin, resistin, adipsin and non-
esteriﬁed fatty acids (NEFAs) after an overnight fast.
All patients affected by impaired fasting glucose (IFG) or impaired
glucose tolerance (IGT) were treated with diet alone. Patients with
overt diabetes mellitus and those receiving hypoglycemic agents were
excluded from this study to avoid the effect of glucotoxicity or of
drugs on the adipokine levels and insulin-sensitivity indexes.
3.1. Hormone and biochemical assays
All biochemical data were collected after overnight fasting. Glyce-
mia,HbA1c and lipid levelsweremeasured in our centralized accredited
laboratory with standard methods. Serum insulin was measured by
ELISA (DRG Instruments GmbH, Germany). The sensitivity of the meth-
od was 1 IU/ml. The normal insulin range (IU/ml) was 5–19. GH levels
were assayed by immunoradiometric assay (Radim, Pomezia, Italy).
The sensitivity of the assays was 0.05 μg/l. The intra- and inter-assay
coefﬁcients of variation (CV) were 4.5 and 7.9%, respectively. Serum
IGF-1 was measured using immunoradiometric assays (Diagnostic Sys-
tem Laboratories Inc., Webster, TX). The normal ranges (for age) were:
118–475 and 118–450 (21–30), 102–400 and 100–390 (31–40),
100–306 and 96–228 (41–50), 95–270 and 90–250 (51–60), 88–250
and 82–200 (61–70), 78–200 and 68–188 μg/l (≥70) for men and
women, respectively. The sensitivity of the assay was 0.8 μg/l. The
intra- and inter-assay CVs were 3.4, 3.0 and 1.5%, and 8.2, 1.5 and 3.7%
for low, medium and high points on the standard curve, respectively.
The BioPlex Pro Human Diabetes 10-plex assay (BioRad, Milan,
Italy) was used to quantitate leptin (ng/ml), resistin (ng/ml) and
visfatin (pg/ml). The BioPlex Pro Human Diabetes Adipsin and
Adiponectin duplex assay (BioRad, Milan, Italy) was used for adipsin
(ng/ml) and adiponectin (μg/ml). Human sOB-R (ng/ml) was assayed
using an ELISA sandwich enzyme immunoassay (Human leptin receptor
ELISA, BioVendor, Heidelberg, Germany). NEFAs (mmol/l) were assayed
using an enzymatic colorimetric method (Randox NEFA assay FA115,
Randox Laboratories, County Antrim, UK).
3.1.1. Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17was used
for data analysis. Baseline characteristics were presented as mean ±
Standard Deviation (SD); rates and proportions were calculated for
categorical data. Thenormality of distributionof thequantitative variables
was assessed by means of the Kolmogorov-Smirnov test. The differences
between the two groups of patients (with controlled or uncontrolled
disease) were evaluated with the Student's t-test. Continuous variables
were analyzed with a one-way ANOVA and the differences between the
groups of patients with different type of treatment were evaluated by
ANOVA for repeated measures with a Bonferroni test for the post hoc
analysis. Simple univariate correlations among continuous variables
with normal distribution were determined by Pearson's test. To evaluate
the independent variables inﬂuencing leptin and visfatin in all acromegal-
ic patients a linear regression model was performed. A p value of b0.05
was considered statistically signiﬁcant.
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4.1. Characteristics of patients grouped according to disease control
The clinical and biochemical features of patients according to disease
control are shown in Table 1.
Group A showed higher DBP (82.9± 12.6 vs. 75.2± 9.5mmHg; p=
0.034), fasting insulin (14.4 ± 12.7 vs. 6.2 ± 4.1 IU/ml; p = 0.034),
Homa-IR (4 ± 2.1 vs. 1.3 ± 0.5; p b 0.001), VAI (3.4 ± 1 vs. 1.3 ± 0.6;
p b 0.001), triglycerides (160.5 ± 33.3 vs. 93.3 ± 24.6 mg/dl; p b
0.001) and lower ISI Matsuda (1.9 ± 0.4 vs. 4.84 ± 1.44; p b 0.001),
HDL cholesterol (43.2 ± 7.45 vs. 53.5 ± 10.1 mg/dl; p b 0.001) than
group B, while no signiﬁcant difference in duration of disease, WC,
BMI, SBP, fasting glucose, Hba1c, total and LDL-cholesterol was found
(Table 1).
In the subgroup of 21 patients, the M value derived from clamp
showed signiﬁcant lower values in group A than group B (1.3 ± 0.6 vs.
2.9 ± 0.8 mg/dl; p b 0.001).
In addition, group A showed signiﬁcantly higher levels of visfatin
(1.51 ± 0.44 vs. 0.21 ± 0.22 pg/ml; p b 0.001) and NEFAs (0.54 ±
0.06 vs. 0.36± 0.01mmol/l; p b 0.001), higher although not signiﬁcant-
ly levels of resistin (1.72 ± 0.62 vs. 1.40 ± 0.58 ng/ml; p = 0.056) and
signiﬁcantly lower levels of leptin (0.89±0.55 vs3.49±1.28 ng/ml; p b
0.001), while no signiﬁcant difference in adiponectin (5.43 ± 4.81 vs.
5.38 ± 3.71 μg/ml; p = 0.965), adipsin (0.26 ± 0.14 vs. 0.30 ±
0.13 ng/ml; p = 0.401) and sOB-R (19.55 ± 8.57 vs. 18.59 ±
4.45 ng/ml; p = 0.965) was found (Table 1).Table 1
Clinical and biochemical features of patients grouped according to disease control.
Acromegalic patients with uncontrolled disease (group
(59%)
Subjects (%)
Gender
Males 19 (57.6)
Females 14 (42.4)
Mean ± SD
Age (years) 53.3 ± 10.5
BMI (kg/m2) 29.4 ± 2.9
Waist circumference (cm) 96.1 ± 11
Visceral adiposity index 3.4 ± 1
Duration of disease (years) 7.5 ± 4.6
Systolic blood pressure (mm Hg) 135.3 ± 24
Diastolic blood pressure (mm Hg) 82.9 ± 12.6
GH nadir after OGTT (μg/l) 11.8 ± 13.7
IGF1 (ULN) 2 ± 0.9
Fasting glucose (mmol/l) 5.9 ± 0.8
Fasting insulin (IU/ml) 14.4 ± 12.7
HbA1c (%) 6.4 ± 1.3
Total cholesterol (mg/dl) 186.4 ± 40.8
HDL cholesterol (mg/dl) 43.2 ± 7.4
LDL cholesterol (mg/dl) 108.9 ± 42.7
Triglycerides (mg/dl) 160.5 ± 33.3
Homa IR 4 ± 2.1
ISI Matsuda 1.9 ± 0.4
M value (clamp)a 1.7 ± 0.7
Leptin (ng/ml) 0.89 ± 0.55
Adiponectin (μg/ml) 5.43 ± 4.81
Resistin (ng/ml) 1.72 ± 0.62
Visfatin (pg/ml) 1.51 ± 0.44
Adipsin (ng/ml) 0.26 ± 0.14
sOB-R (ng/ml) 19.55 ± 8.57
NEFA (mmol/l) 0.54 ± 0.06
OGTT: oral glucose tolerance test.
ULN: upper limit of normal range.
sOB-R = soluble leptin receptor.
NEFAs = non-esteriﬁed fatty acids.
a Clamp was performed in a subgroup of 21 patients, including 11 uncontrolled and 10 cont4.2. Characteristics of patients grouped according to acromegaly treatment
The clinical and biochemical features of patients according to
acromegaly treatment are shown in Table 2.
ND patients showed higher VAI, triglycerides, Homa-IR and lower ISI
Matsuda, M-value compared to any other group of patients and higher
fasting insulin than PE, while no difference in metabolic parameters
was found among SA, PE and SU patients (Table 2).
When we compared the adipokine levels according to treatment for
acromegaly, we found lower levels of leptin in ND patients (0.86 ±
0.66 ng/ml) than in patients treated with SA (2.08 ± 1.67 ng/ml; p =
0.030), PE (2.91 ± 1.28 ng/ml; p = 0.027) or SU (3.33 ± 1.62 ng/ml;
p = 0.031) in concomitant with higher visfatin levels (1.54 ± 0.58 pg/
ml) than SA (0.86 ± 0.62 pg/ml; p = 0.012), PE (0.32 ± 0.51 pg/ml;
p = 0.034) and SU patients (0.48 ± 0.65 pg/ml; p = 0.022), while no
difference in adiponectin, adipsin, resistin, sOB-R and NEFAs was
found (Fig. 1, Table 2).
In univariate analysis, leptinwas found to be correlatedwith GH nadir
(r−0.430; p= 0.009), IGF-1 (r−0.594; p b 0.001), Homa-IR (r−0.446;
p = 0.001), ISI Matsuda (r 0.663; p b 0.001) and VAI (r −0.500; p b
0.001), visfatin was found to be correlated with IGF-1 (r 0.683; p b
0.001), Homa-IR (r 0.558; p b 0.001), ISI Matsuda (r −0.701; p b
0.001), M-value (r −0.447; p = 0.042) and VAI (r 0.724; p b 0.001),
while no correlation was found with WC and BMI. IGF-1, as expected,
correlates with GH nadir (r 0.620; p b 0.001) and also with Homa-IR
(r 0.622; p b 0.001), ISI Matsuda (r −0.575; p b 0.001), M-value
(r 0.616; p = 0.003) and VAI (r 0.595; p b 0.001) (Table 3).A) No. 33 Acromegalic patients with controlled disease (group B) No. 23
(41%)
Subjects (%) p
0.689
12 (52.2)
11 (47.8)
Mean ± SD
56.1 ± 14.2 0.354
29.2 ± 3 0.795
99.2 ± 8.5 0.267
1.3 ± 0.6 b0.001
7.7 ± 4.7 0.926
126.1 ± 14.2 0.159
75.2 ± 9.5 0.034
0.8 ± 0.6 b0.001
0.5 ± 0.2 b0.001
5.7 ± 0.7 0.469
6.2 ± 4.1 0.034
6.1 ± 1.2 0.363
189.8 ± 45.5 0.794
53.5 ± 10.1 b0.001
133.2 ± 48.4 0.313
93.3 ± 24.6 b0.001
1.3 ± 0.5 b0.001
4.8 ± 1.4 b0.001
2.9 ± 0.8 0.001
3.49 ± 1.28 b0.001
5.38 ± 3.71 0.965
1.40 ± 0.58 0.056
0.21 ± 0.22 b0.001
0.30 ± 0.13 0.401
18.59 ± 4.45 0.624
0.36 ± 0.01 b0.001
rolled patients.
Table 2
Metabolic parameters and adipokine levels in acromegalic patients grouped according to acromegaly treatment.
Newly diagnosed
patients (ND)
No. 16 (28.6%)
(M/F: 9/7)
Somatostatin
analogue-treated
patients (SA)
No. 21 (37.5%)
(M/F: 11/10)
Pegvisomant-treated
patients (PE)
No. 12 (21.4%) (M/F: 7/5)
Surgery-treated
patients (SU)
No. 7 (12.5%)
(M/F: 4/3)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD p p1 p2 p3 p4 p5
BMI (kg/m2) 29.7 ± 2.8 29.9 ± 2.9 28.5 ± 2.7 27.2 ± 3.3 1 1 0.472 1 0.298 1
Waist circumference (cm) 93.6 ± 10.1 99.5 ± 10.2 100.8 ± 8.5 96 ± 10.2 0.521 0.415 1 1 1 1
Visceral adiposity index 3.5 ± 1.3 2.3 ± 1 2.1 ± 1.1 1.6 ± 1.4 0.039 0.046 0.012 0.998 0.878 0.981
Fasting glucose (mg/dl) 5.5 ± 0.7 5.9 ± 0.7 5.9 ± 1 6.1 ± 0.5 0.986 1 0.727 0.936 0.561 1
Fasting insulin (IU/ml) 17.4 ± 12.1 8.2 ± 9.2 3.4 ± 0.1 8.0 ± 3.9 0.185 0.003 0.120 0.411 1 0.330
HbA1c (%) 6.3 ± 1.8 6.4 ± 1.2 6.4 ± 0.9 5.7 ± 0.9 1 1 0.481 1 0.225 0.175
Total cholesterol (mg/dl) 198.5 ± 38.2 183.7 ± 46.1 179.8 ± 52.1 186 ± 33.9 0.338 0.362 0.474 1 1 1
HDL cholesterol (mg/dl) 44.1 ± 8.8 48.3 ± 11.6 50.7 ± 8.8 51 ± 8.9 1 0.931 1 0.602 0.610 1
LDL cholesterol (mg/dl) 127.4 ± 38.4 129.8 ± 60.1 88.6 ± 45 104 ± 17.2 1 0.217 0.465 0.348 0.602 1
Triglycerides (mg/dl) 168.3 ± 40.9 124.4 ± 38.3 125.4 ± 38.1 90.5 ± 28.6 0.013 0.048 b0.001 1 0.138 0.195
Homa IR 4.6 ± 1.6 2.6 ± 2.4 1.8 ± 1.5 2.6 ± 1.6 0.031 0.001 0.028 0.853 1 0.937
ISI Matsuda 2.1 ± 0.5 3.3 ± 1.9 3.4 ± 1.8 4.2 ± 1.9 0.019 0.019 0.001 0.987 0.301 0.349
M-value (clamp) a 1.3 ± 0.7 3.2 ± 0.9 2.3 ± 0.1 2.4 ± 0.1 0.013 0.047 0.037 0.207 0.277 0.860
Leptin (ng/ml) 0.86 ± 0.66 2.08 ± 1.67 2.91 ± 1.28 3.33 ± 1.62 0.030 0.027 0.031 0.992 0.443 0.761
sOB-R (ng/ml) 19 ± 10.4 18.93 ± 5.27 21 ± 1.35 16.7 ± 4.1 1 1 1 1 1 1
Adiponectin (ng/ml) 6.76 ± 6.37 5.15 ± 3.56 5.01 ± 1.28 3.89 ± 2.46 1 0.504 0.856 1 1 1
Resistin (ng/ml) 1.75 ± 0.74 1.63 ± 0.51 1.60 ± 0.52 1.47 ± 0.73 1 0.879 1 1 1 1
Visfatin (pg/ml) 1.54 ± 0.58 0.86 ± 0.62 0.32 ± 0.51 0.48 ± 0.65 0.012 0.0034 0.022 0.992 0.696 0.978
Adipsin (ng/ml) 0.28 ± 0.19 0.28 ± 0.11 0.41 ± 0.15 0.23 ± 0.06 1 0.196 1 0.125 1 0.055
NEFAs (mmol/l) 0.53 ± 0.07 0.44 ± 0.11 0.47 ± 0.09 0.47 ± 0.05 0.538 0.240 1 1 1 1
p = difference between ND and SA.
p1 = difference between ND and PE.
p2 = difference between ND and SU.
p3 = difference between SA and PE.
p4 = difference between SA and SU.
p5 = difference between PE and SU.
M/F = males/females.
a Clamp was performed in a subgroup of 21 patients, including 7 ND, 6 SA, 4 PE and 4 SU.
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(B 0.420; p = 0.0029) and VAI (B 0.309; p= 0.010) were the variables
independently associated with visfatin, while only ISI Matsuda (B 0.398;
p = 0.019) was independently associated with leptin. Conversely, no
independent correlations were found between metabolic parameters
and IGF-1, with the exception of Homa-IR (B 0.332; p = 0.049)
(Table 4).
5. Discussion
In the literature data on adipokines, such as adiponectin or leptin, in
acromegaly are numerous but quite contradictory, while the possible
relationship between other adipokines, as visfatin, and GH/IGF I levels
or metabolic parameters have been poorly investigated. In this study,
visfatin was found to correlate to adipose dysfunction and metabolic
impairment in active acromegaly.
Acromegaly is well known to be associated with insulin resistance
and various degrees of carbohydrate intolerance [17,18], although the
pathogenesis of these disturbances is not yet completely known. In
this study, as expected, uncontrolled or untreated patients showed a
worsemetabolic proﬁle, with lower insulin sensitivity, worse lipid proﬁle
and higher visceral adiposity index.We already previously demonstrated
that active acromegaly is strongly associated with visceral adiposity
dysfunction [4,19] and that both SA and SU treatment are able to improve
it, as demonstrated by the signiﬁcant VAI decrease after 12 months of
therapy [20]. The alteration in visceral adiposity, both in excess and in
deﬁciency, has been shown to be a main determinant of insulin resis-
tance in non-acromegalic patients [21,22] and this relationship ismediat-
ed by adipokine secretion that may modulate insulin sensitivity [23].
Acromegaly is characterized by alteration in adipose distribution [5]
and the direct effect of GH on adipose tissue is well known [1]. Therefore,
we hypothesized that the adipose dysfunction in acromegaly is closely
related to insulin resistance and metabolic alterations. For these reasons,we have analyzed some selected adipokines known to have a clear met-
abolic role. Leptin has an endocrine function in body weight regulation
and amutual relationship between leptin andGHhas beendemonstrated
[24]. In this study we found lower leptin levels in acromegalic patients
with uncontrolled than controlled disease, as well as in newly diagnosed
and not treated patients than treated patients, without difference in sOB-
R. These data are consistent with many previous studies which have
demonstrated lower leptin levels in active acromegalic patients with an
increase after surgical or medical treatment [25–27], although other
authors showed overlapped leptin values in many active acromegalic
patients and control subjects or no difference after medical treatment
[28,29]. Interestingly, in our cohort of patients no difference was found
in leptin levels between patients treated with SA, PE or SU, suggesting
the main role of the disease control regardless of the type of treatment.
Whether the leptin levels are inﬂuenced by hormonal or metabolic
parameters is unclear. A correlation with BMI has not been unequivo-
cally demonstrated [25,30], as well as the correlation with GH and IGF-1
levels or insulin levels [25,31,32]. In univariate analysis we found a corre-
lation between leptin and hormonal parameters (both GH and IGF-1),
insulin-sensitivity indexes (Homa-IR, ISI Matsuda, M-value) and adipose
dysfunction (VAI), without correlation with WC and BMI. Nevertheless,
these data have not been conﬁrmed by a linear regression model,
where only insulin sensitivity seems to be the independent factor
inﬂuencing leptin, and these data are partially consistent with some of
the above mentioned studies. For these reasons, we believe that the
hormonal parameters are not major regulators of leptin and that leptin
in acromegaly cannot be considered as a speciﬁc and sensitive index of
severity of disease or adipose dysfunction. Conversely, we found a strong
correlation between visfatin and several hormonal andmetabolic param-
eters in our cohort of patients. Visfatin, prevalently secreted by visceral
adipose tissue, is known to be related with the alteration in visceral
adipose tissue associated with insulin resistance in non-acromegalic
patients [33,34]. Although acromegaly is characterized by both adipose
Fig. 1. Leptin (on the top) and visfatin (on the bottom) levels in acromegalic patients
grouped according to treatment practiced. ND: newly diagnosed without acromegaly
treatment; SA: in therapywith somatostatin analogues; PE: in therapywith pegvisomant;
SU: after surgery.
Table 3
Correlation between leptin, visfatin, IGF-1 andmetabolic parameters (univariate analysis).
Leptin Visfatin IGF-1
r p r p r p
GH nadir −0.430 0.009 0.255 0.133 0.620 b0.001
IGF-1 −0.594 b0.001 0.683 b0.001 – –
Homa IR −0.446 0.001 0.558 b0.001 0.622 b0.001
ISI Matsuda 0.663 b0.001 −0.701 b0.001 −0.575 b0.001
M-value (clamp) a 0.281 0.217 −0.447 0.042 −0.616 0.003
BMI −0.033 0.812 0.008 0.954 0.078 0.580
WC 0.139 0.325 −0.198 0.160 −0.104 0.466
VAI −0.500 b0.001 0.724 b0.001 0.595 b0.001
a Clamp was performed in a subgroup of 21 patients.
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are very scarce and in the few existing studies no difference was report-
ed in visfatin levels between acromegalic patients and controls [35].
In the current study, the patients with uncontrolled or untreated
disease showed higher visfatin, which strongly correlates with IGF-1
levels, insulin sensitivity and visceral adiposity dysfunction. Indeed
the VAI, which is a surrogate index of the adipose dysfunction, and the
M-value, which is considered the gold standard of the insulin sensitivity
evaluation, were found to be the independent variables signiﬁcantly
associated with the visfatin levels. Conversely, no association was
found with IGF-1 levels.
We already demonstrated that acromegalic patients with high VAI
show decreased insulin sensitivity and that the lipotoxicity secondary
to the lipolytic action of GH could be clinically expressed by VAI [4].
These previous data are conﬁrmed by the evidence in this study of
higher NEFA levels in patients with uncontrolled disease, consistent
with the data of Grottoli et al., who suggested the elevated levels of
NEFAs caused by GH-stimulated lipolysis as one of the possible mecha-
nisms leading to insulin resistance in acromegaly [36].
The levels of resistin, a potential marker of insulin resistance [37,38],
were evaluated few times in acromegaly. In this study also resistin levels
showed higher levels in uncontrolled than controlled patients, although
not statistically signiﬁcant, and this ﬁnding is partially consistent with
previous studies. Indeed, other authors have already demonstrated no
signiﬁcant difference in resistin levels between acromegalic patients
and control subjects and no correlation between resistin and GH/IGF Ilevels or insulin resistance indexes [39,40]. Fort these reasons, although
the administration of GH in GH-deﬁcient rats has been shown to increase
mRNA expression of resistin in white adipose tissue [41], in acromegalic
patients GH does not seem to directly affect resistin levels.
Data on adiponectin levels in acromegalic patients are very contro-
versial. Adiponectin is an insulin-sensitizing adipokine expressed in
human adipose cellswith anti-atherogenic and anti-inﬂammatory prop-
erties that plays a role in the pathophysiology of insulin resistance and
metabolic syndrome [42–44]. Both a condition of hypoadiponectinemia
and increased levels of adiponectin in acromegalic patients compared
to control subjects have been demonstrated [35,45]. Silha et al. [39]
showed increased adiponectin levels in acromegalic patients, without
direct or inverse correlation with metabolic or hormonal parameters,
probably because adiponectin are negatively correlated with body fat,
which is reduced in acromegaly [46]. In the current study, we found
no signiﬁcant difference in adiponectin levels between uncontrolled
and controlled patients, as well as in the different treatment groups,
and these results are consistent with those of Ronchi et al. who did not
demonstrate the validity of adiponectin as a marker of cardiovascular
risk, because the lack of correlation with BMI, hormonal and meta-
bolic parameters [47]. Therefore, acromegaly would differ from the
other conditions of insulin resistance that are associated with
hypoadiponectinemia [48,49]. Adipsin levels were found to be corre-
lated with fat mass, metabolic syndrome and insulin secretion in non
acromegalic patients [50–52]. Given the lack of data on adipsin in
acromegaly and its potential metabolic role, we also aimed to analyze
it in our cohort of patients but without ﬁnding any association with
hormonal and metabolic parameters.
We believe that the strength of this study is given by the concomi-
tant evaluation of selected adipokines and different insulin sensitivity
indexes, especially the gold standard hyperinsulinemic euglycemic
clamp, although it was performed only in a subgroup of patients.
Indeed, the evaluation of insulin sensitivity through euglycemic clamp
has been examined in a minority of studies and in smaller cohorts of
patients [53–56]. Conversely, the limitations of this study are given
by the small size of patients in each group of treatment and by the
lack of a control group, because we compared the different acro-
megaly patients groups among themselves. In addition, the cross-
sectional design of the study could represent a limitation which
could affect the reliability of results achieved in relatively small
study groups.
In conclusion we found that in active acromegaly visfatin could
be considered the most useful index of metabolic alterations, such as
insulin resistance and adiposedysfunction, anddisease control regardless
of type of treatment and it seems to better correlate with the metabolic
parameters than IGF-1.
Nevertheless, whether visfatin inﬂuences the metabolic parameters
or otherwise remains to be demonstrated.We believe that the impact of
adipokine status on the clinical and metabolic features in acromegaly
remains to be further investigated and that additional prospective
studies, that include larger study groups, are required to conﬁrm the
real utility of adipokine assessment in usual clinical settings.
Table 4
Independent variables associated with leptin, visfatin and IGF-1 at multivariate analysis.
Independent variables Dependent variable: leptin Dependent variable: visfatin Dependent variable: IGF-1
Β SE p Β SE p Β SE p
GH nadir −0.020 0.023 0.401 – – – 0.059 0.012 0.001
IGF-1 −0.274 0.298 0.365 0.258 0.101 0.022 – – –
Homa IR 0.040 0.132 0.766 −0.088 0.084 0.312 0.332 0.146 0.049
ISI Matsuda 0.398 0.161 0.019 −0.209 0.070 0.010 0.096 0.129 0.475
M-value (clamp) a – – – 0.319 0.145 0.045 −0.261 0.244 0.312
VAI −0.025 0.200 0.903 0.243 0.077 0.007 −0.120 0.146 0.429
a Clamp was performed in a subgroup of 21 patients.
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